These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17065016)

  • 1. Severe neuropathy in a patient with Waldenstrom disease: from a challenging diagnosis to clinical improvement by innovative therapy.
    Bertazzoni P; Andreola G; Laszlo D; Agazzi A; Bassi S; Gigli F; Martinelli G
    Leuk Lymphoma; 2006 Sep; 47(9):1970-2. PubMed ID: 17065016
    [No Abstract]   [Full Text] [Related]  

  • 2. Fludarabine, cyclophosphamide and rituximab (FCR) induced pulmonary hypertension in Waldenstrom macroglobulinemia.
    Lazarevic VLj; Liljeholm M; Forsberg K; Söderberg S; Wahlin A
    Leuk Lymphoma; 2008 Jun; 49(6):1209-11. PubMed ID: 18452089
    [No Abstract]   [Full Text] [Related]  

  • 3. Cryoglobulinaemia identified by repeated analytical failure of laboratory tests.
    Hira-Kazal R; Sayar Z; Kothari J; Ayrton P; Berney S; Maher J
    Lancet; 2014 Jan; 383(9914):382. PubMed ID: 24461124
    [No Abstract]   [Full Text] [Related]  

  • 4. Rituximab-based treatments in Waldenström's macroglobulinemia.
    Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study.
    Laszlo D; Andreola G; Rigacci L; Fabbri A; Rabascio C; Mancuso P; Pruneri G; Radice D; Pinto A; Frigeri F; Calabrese L; Billio A; Bertolini F; Martinelli G
    J Clin Oncol; 2010 May; 28(13):2233-8. PubMed ID: 20368573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe peripheral neuropathy following carfilzomib, rituximab, and dexamethasone for initial treatment of Waldenström's macroglobulinemia.
    Alfaraj WA; Cachia D; Tummala S; Thomas SK; Manasanch EE
    Ann Hematol; 2016 Jan; 95(2):347-8. PubMed ID: 26432713
    [No Abstract]   [Full Text] [Related]  

  • 7. Rituximab-induced life-threatening coagulopathy occurring in a patient with Waldenström macroglobulinemia treated with fludarabine, cyclophosphamide, and rituximab combination.
    Pilorge S; Park S; Dreyfus F; Bouscary D; Tamburini J
    Leuk Lymphoma; 2010 Dec; 51(12):2288-90. PubMed ID: 20929331
    [No Abstract]   [Full Text] [Related]  

  • 8. Waldenström macroglobulinemia of the orbit.
    Ranchod TM; Mansour TN; Fogt F; Gausas RE
    Ophthalmic Plast Reconstr Surg; 2008; 24(1):76-7. PubMed ID: 18209658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Waldenström macroglobulinaemia and intestinal lymphangiectasia.
    Cooke RE; Kalnins RM; Ho WK
    Br J Haematol; 2014 Nov; 167(3):292. PubMed ID: 25039993
    [No Abstract]   [Full Text] [Related]  

  • 10. Complete remission of Waldenström macroglobulinemia with azacitidine and rituximab.
    Weiss L; Melchardt T; Neureiter D; Kemmerling R; Moshir S; Pleyer L; Greil R; Egle A
    J Clin Oncol; 2011 Aug; 29(24):e696-8. PubMed ID: 21730268
    [No Abstract]   [Full Text] [Related]  

  • 11. Waldenström macroglobulinemia: my way.
    Gertz M
    Leuk Lymphoma; 2013 Mar; 54(3):464-71. PubMed ID: 22860921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide and rituximab in Waldenstrom macroglobulinemia.
    Treon SP; Soumerai JD; Branagan AR; Hunter ZR; Patterson CJ; Ioakimidis L; Briccetti FM; Pasmantier M; Zimbler H; Cooper RB; Moore M; Hill J; Rauch A; Garbo L; Chu L; Chua C; Nantel SH; Lovett DR; Boedeker H; Sonneborn H; Howard J; Musto P; Ciccarelli BT; Hatjiharissi E; Anderson KC
    Blood; 2008 Dec; 112(12):4452-7. PubMed ID: 18713945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine as therapy in untreated and relapsed Waldenström's macroglobulinemia.
    Laszlo D; Andreola G; Rigacci L; Fabbri A; Rabascio C; Pinto A; Negri M; Martinelli G
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):130-2. PubMed ID: 21454213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete molecular remission induced by concomitant cladribine--rituximab treatment in a case of multi-resistant hairy cell leukemia.
    Forconi F; Toraldo F; Sozzi E; Amato T; Raspadori D; Lauria F
    Leuk Lymphoma; 2007 Dec; 48(12):2441-3. PubMed ID: 18067021
    [No Abstract]   [Full Text] [Related]  

  • 15. Resolution of Waldenström's macroglubulinemia related isolated neutropenia by immunochemotherapy.
    van Gelder M; van Marion A; Goossens V; Bommer M; Leblond V
    Am J Hematol; 2011 Apr; 86(4):380-2. PubMed ID: 21442645
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia.
    Hivert B; Tamburini J; Vekhoff A; Tournilhac O; Leblond V; Morel P
    Haematologica; 2011 May; 96(5):785-8. PubMed ID: 21393333
    [No Abstract]   [Full Text] [Related]  

  • 17. Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab.
    Rabascio C; Laszlo D; Andreola G; Saronni L; Radice D; Rigacci L; Fabbri A; Frigeri F; Calabrese L; Billio A; Bertolini F; Martinelli G
    Leuk Res; 2010 Apr; 34(4):454-7. PubMed ID: 19647871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unresolved issues in the comparison of therapies and determination of responses in Waldenström macroglobulinemia.
    Peinert S; Seymour JF
    Leuk Lymphoma; 2010 Oct; 51(10):1767-70. PubMed ID: 20919859
    [No Abstract]   [Full Text] [Related]  

  • 19. The efficacy and stem cell toxicity of cladribine and rituximab in the treatment of patients with chronic lymphocytic leukemia: are all purine analogs created equal?
    Tadmor T; Polliack A; Tam CS
    Leuk Lymphoma; 2010 Apr; 51(4):571-3. PubMed ID: 20141447
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical and immunological worsening in a patient affected with Waldenstrom macroglobulinemia and anti-mag neuropathy after treatment with rituximab.
    Gironi M; Saresella M; Ceresa L; Calvo M; Ferrante P; Merli F; Nemni R
    Haematologica; 2006 Jun; 91(6 Suppl):ECR17. PubMed ID: 16785123
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.